TY - JOUR
T1 - Clinical characteristics of hepatocellular carcinoma in Spain. Comparison with the 2008-2009 period and analysis of the causes of diagnosis out of screening programs. Analysis of 686 cases in 73 centers
AU - Rodríguez de Lope, Carlos
AU - Reig, María
AU - Matilla, Ana
AU - Ferrer, María Teresa
AU - Dueñas, Eva
AU - Mínguez, Beatriz
AU - F. Castroagudín, Javier
AU - Ortiz, Inmaculada
AU - Pascual, Sonia
AU - Lledó, José Luis
AU - Gallego, Adolfo
AU - Arenas, Juan I.
AU - Aracil, Carles
AU - Forne, Montserrat
AU - Muñoz, Carolina
AU - Pons, Fernando
AU - Sala, Margarita
AU - Iñarrairaegui, Mercedes
AU - Martin-Llahi, Marta
AU - Andreu, Victoria
AU - Garre, Carmen
AU - Rendón, Paloma
AU - Fuentes, Javier
AU - Crespo, Javier
AU - Rodríguez, Manuel
AU - Bruix, Jordi
AU - Varela, María
PY - 2017/7/21
Y1 - 2017/7/21
N2 - © 2017 Elsevier España, S.L.U. Background and objective In 2010 we published that 53% of cases of hepatocellular carcinoma (HCC) detected in Spain were diagnosed outside the context of standard screening programs, which consequently leads to lower survival rates. The aim of this study was to analyze the current situation and the causes of diagnosis out of screening programs. Material and methods Prospective registry of 73 second- and third-level Spanish healthcare centers carried out between October 1, 2014 and January 31, 2015. The baseline characteristics of the disease and the first treatment administered for the incidental primary liver tumors during such period were recorded. Results A total of 720 patients were included in the study: HCC (n = 686), intrahepatic cholangiocarcinoma (n = 29), hepatic cholangiocarcinoma (n = 2), other (n = 3). HCC characteristics: male 82%; mean age 67 years; cirrhosis 87%; main etiologies: alcohol 35%, HCV 30%, alcohol and HCV 15%, non-alcoholic fatty liver disease 6%; tumor stage: BCLC-0 11%, A 43%, B 19%, C 16% and D 11%; first treatment: transarterial chemoembolization (23%), percutaneous ablation (22%), symptomatic treatment (20%), resection (11%), sorafenib (11%). Three hundred and fifty-six patients (53%) were diagnosed outside of screening programs, mainly owing to the fact that they suffered from an undiagnosed liver disease (76%) and to the poor adherence to the screening program (18%). These patients were mainly male (P < .001), with an alcoholic etiology (P < .001) and active alcohol consumption (P < .001). Moreover, the disease was predominantly diagnosed at more advanced stages (P < .001) and was addressed with less radical treatments (P < .001). Conclusions In Spain, the main cause of diagnosis of a HCC outside the context of a screening program is the absence of a prior diagnosis of a liver disease, particularly in alcohol-consuming men. Detecting a liver disease in asymptomatic populations and improving adherence to screening programs are the main areas that must be subject to improvement in order to improve the early detection of HCC.
AB - © 2017 Elsevier España, S.L.U. Background and objective In 2010 we published that 53% of cases of hepatocellular carcinoma (HCC) detected in Spain were diagnosed outside the context of standard screening programs, which consequently leads to lower survival rates. The aim of this study was to analyze the current situation and the causes of diagnosis out of screening programs. Material and methods Prospective registry of 73 second- and third-level Spanish healthcare centers carried out between October 1, 2014 and January 31, 2015. The baseline characteristics of the disease and the first treatment administered for the incidental primary liver tumors during such period were recorded. Results A total of 720 patients were included in the study: HCC (n = 686), intrahepatic cholangiocarcinoma (n = 29), hepatic cholangiocarcinoma (n = 2), other (n = 3). HCC characteristics: male 82%; mean age 67 years; cirrhosis 87%; main etiologies: alcohol 35%, HCV 30%, alcohol and HCV 15%, non-alcoholic fatty liver disease 6%; tumor stage: BCLC-0 11%, A 43%, B 19%, C 16% and D 11%; first treatment: transarterial chemoembolization (23%), percutaneous ablation (22%), symptomatic treatment (20%), resection (11%), sorafenib (11%). Three hundred and fifty-six patients (53%) were diagnosed outside of screening programs, mainly owing to the fact that they suffered from an undiagnosed liver disease (76%) and to the poor adherence to the screening program (18%). These patients were mainly male (P < .001), with an alcoholic etiology (P < .001) and active alcohol consumption (P < .001). Moreover, the disease was predominantly diagnosed at more advanced stages (P < .001) and was addressed with less radical treatments (P < .001). Conclusions In Spain, the main cause of diagnosis of a HCC outside the context of a screening program is the absence of a prior diagnosis of a liver disease, particularly in alcohol-consuming men. Detecting a liver disease in asymptomatic populations and improving adherence to screening programs are the main areas that must be subject to improvement in order to improve the early detection of HCC.
KW - Hepatocellular carcinoma
KW - Incidence
KW - Screening
KW - Treatment
U2 - 10.1016/j.medcli.2016.12.048
DO - 10.1016/j.medcli.2016.12.048
M3 - Article
SN - 0025-7753
VL - 149
SP - 61
EP - 71
JO - Medicina Clinica
JF - Medicina Clinica
IS - 2
ER -